Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Clinical trial NCT04390763 · TERMINATED
Trial details
- NCT number
- NCT04390763
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-16
- Primary completion
- 2024-04-26
- Enrollment
- 164
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.